Literature DB >> 29476349

Therapeutic Drug Monitoring of Beta-Lactams and Other Antibiotics in the Intensive Care Unit: Which Agents, Which Patients and Which Infections?

Anouk E Muller1,2, Benedikt Huttner3, Angela Huttner4.   

Abstract

Antibiotics are among the medications most frequently administered to the critically ill, a population with high levels of intra- and inter-individual pharmacokinetic variability. Our knowledge of the relationships among antibiotic dosing, exposure and clinical effect in this population has increased in recent decades. Therapeutic drug monitoring (TDM) of serum antibiotic concentrations is the most practical means of assessing adequate antibiotic exposure, though until recently, it has been underutilised for this end. Now TDM is becoming more widespread, particularly for the beta-lactam antibiotics, a class historically thought to have a wide therapeutic range. We review the basic requirements, indications, and targets for effective TDM of the glycopeptides, aminoglycosides, quinolones and beta-lactam antibiotics in the adult intensive-care setting, with a special focus on TDM of the beta-lactam antibiotics, the most widely used antibiotic class.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29476349     DOI: 10.1007/s40265-018-0880-z

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  26 in total

Review 1.  Piperacillin-Tazobactam in Intensive Care Units: A Review of Population Pharmacokinetic Analyses.

Authors:  Ibrahim El-Haffaf; Jean-Alexandre Caissy; Amélie Marsot
Journal:  Clin Pharmacokinet       Date:  2021-04-20       Impact factor: 6.447

2.  Meropenem Target Attainment and Population Pharmacokinetics in Critically Ill Septic Patients with Preserved or Increased Renal Function.

Authors:  Matthias Gijsen; Omar Elkayal; Pieter Annaert; Ruth Van Daele; Philippe Meersseman; Yves Debaveye; Joost Wauters; Erwin Dreesen; Isabel Spriet
Journal:  Infect Drug Resist       Date:  2022-01-08       Impact factor: 4.003

Review 3.  [Therapeutic drug monitoring and pharmacokinetic models as a strategy for rational antibiotic therapy in intensive care patients].

Authors:  Lea Marie Schatz; Michael Zoller; Christina Scharf; Uwe Liebchen
Journal:  Anaesthesiologie       Date:  2022-06-15

4.  Evaluation of a Meropenem and Piperacillin Monitoring Program in Intensive Care Unit Patients Calls for the Regular Assessment of Empirical Targets and Easy-to-Use Dosing Decision Tools.

Authors:  Ferdinand Anton Weinelt; Miriam Songa Stegemann; Anja Theloe; Frieder Pfäfflin; Stephan Achterberg; Franz Weber; Lucas Dübel; Agata Mikolajewska; Alexander Uhrig; Peggy Kiessling; Wilhelm Huisinga; Robin Michelet; Stefanie Hennig; Charlotte Kloft
Journal:  Antibiotics (Basel)       Date:  2022-06-02

5.  How to Manage Pseudomonas aeruginosa Infections.

Authors:  Matthaios Papadimitriou-Olivgeris; Damien Jacot; Benoit Guery
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 3.650

6.  Usefulness of therapeutic drug monitoring of piperacillin and meropenem in routine clinical practice: a prospective cohort study in critically ill patients.

Authors:  Joan Antoni Schoenenberger-Arnaiz; Faten Ahmad-Diaz; Mar Miralbes-Torner; Ana Aragones-Eroles; Manuel Cano-Marron; Mercedes Palomar-Martinez
Journal:  Eur J Hosp Pharm       Date:  2019-02-27

7.  Too Much of a Good Thing: Defining Antimicrobial Therapeutic Targets to Minimize Toxicity.

Authors:  Kevin J Downes; Jennifer L Goldman
Journal:  Clin Pharmacol Ther       Date:  2021-02-27       Impact factor: 6.875

8.  Right Dose, Right Now: Development of AutoKinetics for Real Time Model Informed Precision Antibiotic Dosing Decision Support at the Bedside of Critically Ill Patients.

Authors:  Luca F Roggeveen; Tingjie Guo; Ronald H Driessen; Lucas M Fleuren; Patrick Thoral; Peter H J van der Voort; Armand R J Girbes; Rob J Bosman; Paul Elbers
Journal:  Front Pharmacol       Date:  2020-05-15       Impact factor: 5.810

9.  Pharmacokinetic/Pharmacodynamic Target Attainment Based on Measured versus Predicted Unbound Ceftriaxone Concentrations in Critically Ill Patients with Pneumonia: An Observational Cohort Study.

Authors:  Matthias Gijsen; Erwin Dreesen; Ruth Van Daele; Pieter Annaert; Yves Debaveye; Joost Wauters; Isabel Spriet
Journal:  Antibiotics (Basel)       Date:  2021-05-11

Review 10.  Setting the Beta-Lactam Therapeutic Range for Critically Ill Patients: Is There a Floor or Even a Ceiling?

Authors:  Erin F Barreto; Andrew J Webb; Gwendolyn M Pais; Andrew D Rule; Paul J Jannetto; Marc H Scheetz
Journal:  Crit Care Explor       Date:  2021-06-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.